Skip to main content
Clinical Trials/NCT03452462
NCT03452462
Completed
N/A

Electrical Resynchronization and Acute Hemodynamic Effects of Direct His Bundle Pacing Compared to Biventricular Pacing

University Hospital, Geneva1 site in 1 country19 target enrollmentApril 1, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cardiac Pacing, Artificial
Sponsor
University Hospital, Geneva
Enrollment
19
Locations
1
Primary Endpoint
Left ventricular activation time
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The aims are to compare Direct His Bundle Pacing (DHBP) with biventricular pacing (BiV) in terms of electrical resynchronization using electrocardiographic imaging (ECGI) and also in terms of acute hemodynamical effect using finger plethysmography and conduction velocimetry. The study will be a randomized crossover design with acute measurements.

Detailed Description

By recruiting native conducting tissue to relay electrical activation of the ventricles via the Purkinje fibre network, DHBP may potentially achieve greater electrical resynchronization and hemodynamic benefit compared to BiV where the electrical activation wavefronts propagate from two discrete pacing sites. Electrical synchrony achieved by these pacing modes have however never been compared. Furthermore, the acute hemodynamic effect of DHBP has been compared to BiV only in a small single study to date. The aims are to compare DHBP with BiV in terms of electrical resynchronization using electrocardiographic imaging (ECGI) and also in terms of acute hemodynamical effect using finger plethysmography and conduction velocimetry. The primary endpoint will be left ventricular activation time, with secondary endpoints including various electrical (right ventricular activation time, total ventricular activation time etc) and hemodynamic parameters (systolic pressure, cardiac output, cardiac contractility). It is expected that DHBP offers shorter left ventricular activation time (i.e. better synchrony) and hemodynamic benefit compared to BiV.

Registry
clinicaltrials.gov
Start Date
April 1, 2019
End Date
November 26, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Haran Burri, MD

Professor

University Hospital, Geneva

Eligibility Criteria

Inclusion Criteria

  • Treatment of heart failure with a standard indication for CRT (NYHA III-IV, LVEF \< 35% and QRS \> 130ms; or LVEF\< 40% and requirement for frequent ventricular pacing, irrespective of baseline QRS duration) and optimal medical treatment.
  • Permanent atrial fibrillation (allowing connection of the DHBP lead to the atrial port).
  • Patients implanted with 1) a CRT pacemaker or CRT defibrillator 2) a His lead with selective or non-selective DHBP, connected to the atrial port of the generator 3) a functional right ventricular lead and 4) a functional coronary sinus lead.
  • DHBP with selective or non-selective His capture

Exclusion Criteria

  • Age \<18 years
  • Pregnancy
  • Inability to undergo CT or an MRI (e.g. due to severe claustrophobia)
  • Inability or refusal to sign the patient informed consent form.

Outcomes

Primary Outcomes

Left ventricular activation time

Time Frame: 5 minutes

Duration of left ventricular electrical activation

Secondary Outcomes

  • Right ventricular activation time(5 minutes)
  • Cardiac output(5 minutes)
  • Systolic pressure(5 minutes)
  • Total ventricular activation time(5 minutes)
  • Cardiac contractility(5 minutes)

Study Sites (1)

Loading locations...

Similar Trials